A new treatment to reduce inflammation in inflammatory bowel disease
Small molecule inhibitor of CD40 signaling for the control of inflammatory bowel disease
This study is looking at a new treatment that could help people with inflammatory bowel disease (IBD) by using a small molecule to reduce inflammation safely, without raising the risk of blood clots or infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11103410 on NIH RePORTER |
What this research studies
This research focuses on developing a small molecule that inhibits CD40 signaling to control inflammation in patients with inflammatory bowel disease (IBD). The approach aims to block the interaction between CD40 and an adaptor protein, which has shown promise in reducing inflammation without increasing the risk of thrombosis or opportunistic infections. The researchers have identified a compound that effectively diminishes intestinal inflammation in mouse models and are working on optimizing its properties for better efficacy. This innovative strategy could provide a safer alternative to existing therapies for IBD patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who have not responded well to current therapies.
Not a fit: Patients with mild IBD who are effectively managed with existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, safer treatment option for patients suffering from inflammatory bowel disease.
How similar studies have performed: Previous clinical trials have shown that targeting the CD40 pathway can reduce inflammation, but this approach aims to improve safety and efficacy, making it a novel endeavor.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Subauste, Carlos S — Case Western Reserve University
- Study coordinator: Subauste, Carlos S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.